The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Massively parallel de novo protein design for targeted therapeutics
Open accessAbstract
De novo protein design holds promise for creating small stable proteins with shapes customized to bind therapeutic targets. We describe a massively parallel approach for designing, manufacturing and screening mini-protein binders, integrating large-scale computational design, oligonucleotide synthesis, yeast display screening and next-generation sequencing. We designed and tested 22,660 mini-proteins of 37-43 residues that target influenza haemagglutinin and botulinum neurotoxin B, along with 6,286 control sequences to probe contributions to folding and binding, and identified 2,618 high-affinity binders. Comparison of the binding and non-binding design sets, which are two orders of magnitude larger than any previously investigated, enabled the evaluation and improvement of the computational model. Biophysical characterization of a subset of the binder designs showed that they are extremely stable and, unlike antibodies, do not lose activity after exposure to high temperatures. The designs elicit little or no immune response and provide potent prophylactic and therapeutic protection against influenza, even after extensive repeated dosing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The design of proteins that bind to a specific site on the surface of a target protein using no information other than the three-dimensional structure of the target remains a challenge1–5.”
From Design of protein-binding proteins from the target structure alone (2022) · cites this paper as [1]
In the citing paper
“Most current computational methods used to design proteins that bind to a target surface utilize information derived from structures of the native complex on specific side-chain interactions or protein backbone placements optimal for binding1–3.”
From Design of protein-binding proteins from the target structure alone (2022) · cites this paper as [1]
In the citing paper
“Protein1,5, peptide36 and small-molecule inhibitors37 have been designed to bind to the stem region of group 1 HA and neutralize influenza A viruses, but none recognize the group 2 HA.”
From Design of protein-binding proteins from the target structure alone (2022) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of simple potential functions for simulating liquid water
Jorgensen, W. L., Chandrasekhar, J., Madura, J., Impey, R., & Klein, M. (1983) · The Journal of Chemical Physics · doi:10.1063/1.445869 · Cited by 38,397
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
A smooth particle mesh Ewald method
Essmann, U., Perera, L., Berkowitz, M., Darden, T., Lee, H.-C., & Pedersen, L. (1995) · The Journal of Chemical Physics · doi:10.1063/1.470117 · Cited by 21,378
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
GROMACS: Fast, flexible, and free
van der Spoel, D., Lindahl, E. R., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. C. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20291 · Cited by 19,461
LINCS: A linear constraint solver for molecular simulations
Hess, B., Bekker, H., Berendsen, H. J. C., & Fraaije, J. G. E. M. (1997) · Journal of Computational Chemistry · doi:10.1002/(sici)1096-987x(199709)18:12 · Cited by 18,479
Canonical sampling through velocity rescaling
Bussi, G., Donadio, D., & Parrinello, M. (2007) · The Journal of Chemical Physics · doi:10.1063/1.2408420 · Cited by 18,327
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Cited by
Sorted by citations
Items 401–457 of 457
RPtag as an Orally Bioavailable, Hyperstable Epitope Tag and Generalizable Protein Binding Scaffold
DeRosa, J. R., Moyer, B. S., Lumen, E., Wolfe, A. J., Sleeper, M. B., Bianchi, A. H., Crawford, A. J., McGuigan, C., Wortel, D., Fisher, C., et al. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00170
Kaushik, A. C., Mehmood, A., Khan, M. T., Kumar, A., Dai, X., & Wei, D. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1713894
RetractedSemi-rational Design of Target-binding Small Proteins for Cancer Treatment
Kadonosono, T., & Kizaka‐Kondoh, S. (2020) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.19-00187-4
Engineering and Delivery of Synthetic Chromatin Effectors
Tekel, S. J. (2019)
Engineering a CD19-Based Bispecific Molecule for CAR T Cell Therapy
Schrack, I. (2018) · University of Minnesota Digital Conservancy (University of Minnesota)
De novo design of ACE2 based peptide; a potential candidate for COVID-19 therapeuticsPreprint
Basit, A., Asif, M., & Rehman, S. U. (2021) · Research Square · doi:10.21203/rs.3.rs-175669/v1
“De novo protein design is a novel approach used to optimize the binding interface of protein-protein interactions by mutating the residues into favorable mutants which provide new binding interactions with increased binding a nity and preserved secondary structure [17].”
MethodBurnside, D. J. (2019) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2019-13862
Native state of natural proteins optimises local entropyPreprint
Negri, M., Tiana, G., & Zecchina, R. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2111.12987
“The problem has regained importance in more recent years, when it has become feasible to design proteins de novo with custom functions, and thus it has become critical to understand which conformations can be best designed [2].”
BackgroundTobin, A. R., Crow, R., Urusova, D. V., Klima, J. C., Tolia, N. H., & Strauch, E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.05.479252
“A DNA sequence of the amino acid sequence of the newly designed proteins was then 164 generated using DNAworks(30, 31), and sequences were ordered in form of a 230 bp long 165 oligonucleotide pool together which also contained adapters for cloning into a yeast surface 166 expression plasmid as reported before(32).”
MethodFaculty Opinions recommendation of Transferrin receptor targeting by de novo sheet extension.
Okada, T. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.739970477.793585940
Koehl, P. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.739098540.793583440
Dods, R. F. (2019) · Springer eBooks · doi:10.1007/978-3-030-28303-2_3
Bonadio, A., Wenig, B. L., Hockla, A., Radisky, E. S., & Shifman, J. M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.29.522231
“While designing protein binders typically requires multiple cycles of design and testing with sometimes tens of thousands of designs being evaluated (12, 46, 47), in the current work we decided to increase the success of the loop designs by constructing a focused library of NTIMP2 variants where loop randomization was…”
MethodKomp, E., Phillips, C., Alanzi, H. N., Zorman, M. L., & Beck, D. A. C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.06.579188
Albanese, K. I., Barbe, S., Tagami, S., Woolfson, D. N., & Schiex, T. (2025) · Nature Reviews Methods Primers · doi:10.1038/s43586-025-00383-1 · Cited by 104
“On the other hand, more intricate high-throughput methods are applied to select the best sequence from designed protein libraries, as seen in various recent CPD projects 9,273,276,305 .”
SARS-CoV-2 spike protein binding ligands and its application in COVID-19 therapeutics
Zant, W. V., da Silva, G. F., Magalhães, M. D. L. B., & Ray, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95646-8.00028-7
Li, D., Zhu, Y., Zhang, W., Liu, J., Yang, X., Liu, Z., & Wei, D. (2024) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-024-00662-7
“…achievements have emerged, including protein design from sequences [2], protein complexes design from sequences [3], protein design from scaffolds [4, 5], protein design from scratch [6], target driven ligand protein design [7], as well as the AlphaFold3 and RoseTTAFold All Atom [8] universal…”
Hoja didáctica: Premio Nobel de Química 2024
Arreola, M. I. P., Huerta‐Lavorie, R., & Rodes, R. M. C. (2025) · Educación Química · doi:10.22201/fq.18708404e.2025.1.90698
Oligomerization Function of the Native Exon 5 Sequence of Ameloblastin Fused with Calmodulin
Zouharová, M., Heřman, P., Bednářová, L., Vetyskova, V., Hadravová, R., Postulkova, K., Zemanová, L., Vondrášek, J., & Bousova, K. V. (2025) · ACS Omega · doi:10.1021/acsomega.4c07953
Biomolecular Structures: Prediction, Identification and Analyses
Kumar, P., Halder, S., & Bansal, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-95502-7.00301-8
Neural network conditioned to produce thermophilic protein sequences can increase thermal stability
Komp, E., Phillips, C., Lee, L., Fallin, S. M., Alanzi, H. N., Zorman, M. L., McCully, M. E., & Beck, D. A. C. (2025) · Scientific Reports · doi:10.1038/s41598-025-90828-0
Functional Assays for Screening Protein Biotherapeutics
Beresini, M. H., & Loyet, K. M. (2025) · Wiley eBooks · doi:10.1002/9781394236145.ch10
Proteínas de novo: del diseño a la funcionalización
Rodríguez-Meza, O., Costas, M., & Fernández‐Velasco, D. A. (2025) · Educación Química · doi:10.22201/fq.18708404e.2025.3.90539
Self-citationKostin, N. N., Bobik, T. V., Коновалова, Е. В., Kocharovskaya, M. V., Simonova, M. A., Rushkevich, N. Y., Mokrushina, Y. A., Skryabin, G. A., Kalinin, R. S., Kovalchuk, S. I., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-12444-2
In-Depth Review of Advanced Techniques in Protein Engineering in Therapeutic Innovations
Chinnappan, S., Suhail, M., & Ranganathan, V. (2025) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2025.00493
Protein A-like peptide generation based on generalized diffusion model
Zhou, T., Zhang, S., Song, H., He, Q., Fang, C., & Lin, X. (2025) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-025-00653-w
“…computational protein design has achieved remarkable progress, including the design of novel 3D folds [17], enzymes, and complexes [18], as well as immune signaling proteins [19, 20], targeted therapeutic proteins [21, 22], protein switches [23, 24], and self-assembling proteins [25, 26].”
Automated and modular protein binder design with BinderFlowPreprint
Chacón-Sánchez, C., González-Rodríguez, N., Llorca, Ó., & Fernández-Leiro, R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.10.675490
Matsubara, D. K., Park, P., Cuccovia, I. M., & Chaimovich, H. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.06.680738
“De novo designed miniprotein binders provide an attractive alternative [32], [33].”
Lv, H., Huan, Y. W., Pholcharee, T., Teo, Q. W., Liu, W., Gopal, A. B., Choi, D., Ardagh, M. R., Tan, T. J. C., Sun, Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.06.687086
Min, X., Yang, C., Xie, J., Huang, Y., Liu, N., Jin, X., Wang, T., Kong, Z., Lu, X., Ge, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26671197
Calman, I., Shaykhalishahi, H., Sangkhapreecha, P., & Bachas, S. T. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.27.696647 · Cited by 1
Wei, Z., Wei, L., Wu, Z., Hu, Y. A., Fang, Y., Miaomiao, G., Xing, B., Weng, J., Liu, S., & Ming, K. (2026) · Research Square · doi:10.21203/rs.3.rs-8645836/v1
Protein Trimerization and Viral Fusion: Structural Insights and Therapeutic Applications
Mayandi, V., Majumdar, D., Shrestha, P., Kousoulas, K. G., & Jois, S. D. S. (2026) · Challenges and advances in computational chemistry and physics · doi:10.1007/978-3-032-07880-3_8
Qian, Y., Yan, W., Xu, F., Liu, Y., Chen, F., Lu, Y., Zhang, Z., Gu, A., Yu, R., Fang, Z., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.28.702218
Khakerwala, Z., Kumar, A., Gaikwad, S. S., Barik, T., Singh, S., Gupta, G. D., & Makde, R. D. (2025) · Protein Engineering Design and Selection · doi:10.1093/protein/gzag004
Site-specific photosensitizer conjugation and anti-viral application of protein targeting SARS-CoV-2
Jiang, Y., Zou, C., Zhu, S., Fang, X., Zhang, X., Zhou, X., & Huang, M. (2026) · Dyes and Pigments · doi:10.1016/j.dyepig.2026.113660
Xu, L., Ren, Y., Wang, T., Li, H., Yao, Y., Liu, L., Sun, K., & Lu, P. (2026) · Advanced Science · doi:10.1002/advs.202515425
“An oligonucleotide pool was synthesized by Agilent Technologies [ 72 ].”
Rudzińska‐Szostak, E., & Berlicki, Ł. (2026) · Tetrahedron Chem · doi:10.1016/j.tchem.2026.100161
Computational design of an ultrapotent deltacoronavirus miniprotein inhibitor
Avery, N. G., Yoshiyama, C. N., Taylor, A. L., Park, Y., Asarnow, D. E., Perruzza, L., Brown, J. T., Corti, D., Benigni, F., Starr, T. N., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2533456123
“Although miniprotein inhibitors have been previously shown to have low immunogenicity and to retain efficacy after repeat dosing in mouse models (66, 67), future studies are needed to assess the immune response to monovalent and multivalent miniproteins in humans.”
Development of Miniprotein Binders to Inhibit VEGF-Induced Corneal Neovascularization
Adams, N. A., Alaniz, M. M., Wuppukondur, S. N., Schill, A., Alabi, Z. O., Şen, M., Coulson‐Thomas, V. J., & Gesteira, T. F. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.5.61
“13,14 Unlike conventional antibodies, miniproteins can be engineered for high thermal and proteolytic stability, potentially leading to extended half-lives and less frequent dosing.”
Tools For Building Artificial Biological Nanostructures
Bradford, T. S., Hutchings, S., Liston, J. D., Pakosz, Z., Sanderson, A., Shaukat, A., Bentham, A. R., Lin, T., Stępień, P., & Heddle, J. G. (2026) · ACS Nano · doi:10.1021/acsnano.5c14315
Ming, K., Hu, Y., Xing, B., Chen, M., Chen, Y., Chen, X., Geng, M., Wu, Z., Liu, Y., Wei, L., et al. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103336
De Novo Synthesis in Cancer Immunotherapy: Applications and Prospects
Yang, J., Wu, Y., & Luo, J. (2026) · MedComm · doi:10.1002/mco2.70847
State-selective inhibition of alpha-synuclein aggregation by de novo oligomer-binding proteinsPreprint
Zhang, Y., Han, H. L., Ortigosa-Pascual, L., Miles, U. Z., Wei, J., Berkowicz, L. E., Snow, F., Tu, D., Meisl, G., Sansaria, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.13.738012 · Cited by 1
“A modality that engages the toxic oligomeric species directly is therefore attractive, and designed proteins carry practical advantages, being smaller, more stable, and genetically encodable( 47 ).”
Intelligent antigen design combined with yeast display enhances targeted immune responses
Ma, Y.-F., Yin, G.-H., Pan, Y. L., & Liu, Y. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag393
“These epitopes can be grafted onto natural protein scaffolds or reconstructed using de novo scaffolds [ 17– 19].”
Computational Platforms for Membrane-Active Peptide Therapeutic Design
Zan, B., Chen, C. H., Sabha, M., Wu, K., Kadri, M., Nwajiaku, O. L., Hoogland, D., Ulmschneider, J. P., & Ulmschneider, M. B. (2026) · Chemical Reviews · doi:10.1021/acs.chemrev.6c00100
Scalable Production of a De Novo SARS-CoV-2 Antiviral Miniprotein in Escherichia coli
Shin, J., Kim, E.-M., Jang, J.-H., Jee, S.-W., Kim, S.-H., Yu, S. G., Yoon, M., Craig, D., Swoyer, R., Patel, S., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18091110
“Foundational work by Chevalier et al. [16] established massively parallel design–build–test cycles, generating more than 22,000 miniproteins that target influenza hemagglutinin and botulinum neurotoxin with picomolar binding affinities [17].”
Self-citationQian, Y., Yan, W., Xu, F., Liu, Y., Chen, F., Lu, Y., Zhang, Z., Gu, A., Yu, R., Fang, Z., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115355
Random in vitro Protein single-Loop Engineering (RiPLE) by mRNA displayPreprint
Colas, K., Ko, T., Philippe, G. J.-B., & Suga, H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.21.753128
Niazi, S. K., Magoola, M., & Mariam, Z. (2026) · npj Drug Discovery. · doi:10.1038/s44386-026-00084-z
“Theythenincorporatethe outcomesintocomputationalmodels 92 .”
BindingDB Entry 50014835: Computational Design of Potent D-Peptide Inhibitors of SARS-CoV-2.
BindingDB (2023) · UC San Diego · doi:10.7270/q2hq43sk
BindingDB Entry 50015742: Miniproteins in medicinal chemistry.
BindingDB (2023) · UC San Diego · doi:10.7270/q2zs31g2
Metadata
- Authors
- Chevalier, A., Silva, D.-A., Rocklin, G. J., Hicks, D. R., Vergara, R., Murapa, P., Bernard, S. M., Zhang, L., Lam, K.-H., Yao, G., Bahl, C. D., Miyashita, S.-I., Goreshnik, I., Fuller, J. T., Koday, M. T., Jenkins, C. M., Colvin, T., Carter, L., Bohn, A., Bryan, C. M., Fernández-Velasco, D. A., Stewart, L., Dong, M., Huang, X., Jin, R., Wilson, I. A., Fuller, D. H., & Baker, D.
- Affiliations
- University of Washington (US)
- Scripps Research Institute (US)
- Chinese Academy of Sciences (CN)
- University of California, Irvine (US)
- Boston Children's Hospital (US)
- Hong Kong University of Science and Technology (HK)
- Corresponding author
- Baker, David
- ORCID
- Chevalier, Aaron
- Silva, Daniel-Adriano
- Hicks, Derrick R.
- Vergara, Renan
- Murapa, Patience
- Bernard, Steffen M.
- Zhang, Lu
- Lam, Kwok-Ho
- Yao, Guorui
- Bahl, Christopher D.
- Miyashita, Shin-Ichiro
- Goreshnik, Inna
- Fuller, James T.
- Jenkins, Cody M.
- Carter, Lauren
- Bryan, Cassie M.
- Stewart, Lance
- Dong, Min
- Huang, Xuhui
- Jin, Rongsheng
- Wilson, Ian A.
- Fuller, Deborah H.
- Baker, David
- Venue
- Nature
- Published
- 2017-09-27
- Volume
- 550
- Issue
- 7674
- Pages
- 74-79
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5802399
- OpenAlex
- W2759860792
- Cited by
- 453
- References
- 48
- Citations by year
- 2026: 28 · 2025: 57 · 2024: 48 · 2023: 42 · 2022: 59 · 2021: 55 · 2020: 57 · 2019: 53 · 2018: 48 · 2017: 6
- FWCI
- 18.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- King Abdullah University of Science and Technology Repository (King Abdullah University of Science and Technology) (submittedVersion)
- Funders
- National Institutes of Health (1s10od021527-01, 5t32ai007354-30)
- National Institute of General Medical Sciences (P41GM103403)
- National Institute of Allergy and Infectious Diseases (R41AI122431, R01AI091823, R56AI127371, R56AI117675, R21AI119258, R33AI119258, R21AI123920, T32-AI007354., R01AI125704)
- National Institute of Neurological Disorders and Stroke (R01NS080833)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- de novo protein design, miniproteins, protein binders, influenza haemagglutinin, botulinum neurotoxin B, oligonucleotide synthesis, protein stability, antiviral agents, prophylactic protection, antibody alternatives, immune response
- MeSH terms
- Botulinum Toxins, Computer Simulation, Hot Temperature, Humans, Influenza, Human, Protein Binding, Proteins, Temperature, Drug Design, Protein Engineering, Hemagglutinin Glycoproteins, Influenza Virus, Protein Stability, Molecular Dynamics Simulation, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
